Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

BlueWind Medical

435 views

Published on

Delivering new models of care through large-scale digital solutions
Day One, Pop-up University 7, 15.00

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

BlueWind Medical

  1. 1. September 2016
  2. 2. Neurostimulation Transformed 2
  3. 3. Urinary Incontinence – Underserved Patient Population People in the UK suffer from Urinary Incontinence1 (over 200 Million people worldwide) 1. http://www.nhs.uk/conditions/Incontinence-urinary/Pages/Introduction.aspx (accessed 31/8/2016) 2. Irwin DE, Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006 Jan;97(1):96-100. 3. Turner DA et al, The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int. 2004 Jun;93(9):1246-52. 3-6 Million Of patients with OAB and Incontinence suffer from Depression2 40% Patient report: social anxiety, withdrawal from day to day activities 3 £536M NHS cost to treat urinary incontinence (1999/2000 prices)3.
  4. 4. Sacral Nerve Stimulation: Effective, but Complex and Expensive (source: MDT InterStim Clinical Summary) Lifetime NHS cost of Sacral Nerve Stimulation1, not taking into account complications £24,000 Of patients required surgical intervention due to adverse event %15-42% 1. Assuming 2 device replacement over lifetime: £10482 per initial implant and £6700 for each replacement 4
  5. 5. BlueWind System – Minimally Invasive Neurostimulation Small Passive Implant External Control Unit Physician Programmer • The implant is a micro (0.3cc) neuro- stimulators placed at the desired treatment site, adjacent to the target nerve. • The implant is then wirelessly powered and controlled by an external device Closed loop RF energy and data transfer 5
  6. 6. Clinical Improvement: UI Response 6 36 patient study conducted in the UK and Belgium BlueWind OAB clinical results are comparable to competing neurostimulation solutions, without the invasive pelvic procedure 6.7 3.9 4.1 3.9 3.1 2.1 2.1 2.2 1.8 1.4 1.2 1.10 1 2 3 4 5 6 7 8 Baseline (n=29) Month 1 (n=28) Month 3 (n=29) Month 6 (n=29) Perday Leaks/day Pads change/day Leaks severity
  7. 7. 7 Cost Drivers  Simplified procedure, 30 min under local Anesthesia  Lower complication rate  1/36 required surgical intervention  No batteries  no replacement procedures  Treatment efficacy  lower ongoing treatment cost
  8. 8. Conclusion A study investigator: “All patients were given the option of enrolling in this BlueWind study or receiving a Sacral neurostimulation device. 100% chose the BlueWind device.” 8
  9. 9. Sep 2016 Thank You

×